- Prev Rank-
- LocationLa Jolla, Calif.
- SectorHealth Care
- F1000 Rank-
- G500 Rank-
- Current Streak-
This biotechnology firm generates most of its revenue in two ways—by partnering with other pharmaceutical companies, which pay royalties and license fees for use of Ligand’s drugs, and through sales of the company’s “drug reformulation technology,” Captisol. Acquired by Ligand in 2011, Captisol enables the creation of new/improved drugs by improving the solubility, stability and dosing of active pharmaceutical ingredients (to date, six have been approved by the FDA). It also contributed $19 million of the company’s $49 million total revenues last year, and accounted for just over half of 2013 revenue growth. —N.S.
La Jolla, Calif.
Revenue, Net Income
|Revenue Past Four Quarters|
|Net Income Past Four Quarters||12|
Growth Rates & Ranks
|EPS Growth Rank||39|
|EPS 3 yr Annual Growth Rate Pct||66|
|Revenue Growth Rank||38|
|Rev 3 yr Annual Growth Rate||33|
|Total Return 3 yr Annual Rate||73|
|Total Return Rank|
|Beat S&P 3 yr Annual Growth Rate?|
|P/E current fiscal year profits (est.)|